Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 17

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
 held in trust(112)— TOTAL STOCKHOLDERS’ EQUITY1,072,169 1,324,805 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$1,196,031 $1,434,592 

See the accompanying notes to these unaudited condensed consolidated financial statements.

3

Table of Contents

Crinetics Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share data)

(unaudited)

Three months ended September 30,Nine months ended September 30,2025202420252024Revenues$143 $— $1,535 $1,039 Operating expenses:Research and development90,464 61,905 247,005 173,590 Selling, general and administrative52,265 25,892 137,633 71,558 Total operating expenses142,729 87,797 384,638 245,148 Loss from operations(142,586)(87,797)(383,103)(244,109)Other income (expense):Interest income12,544 11,006 40,833 27,067 Other expense, net(49)(37)(232)(301)Total other income, net12,495 10,969 40,601 26,766 Loss before equity method investment(130,091)(76,828)(342,502)(217,343)Loss on equity method investment— — — (470)Net loss$(130,091)$(76,828)$(342,502)$(217,813)Net loss per share:Net loss per share — basic and diluted$(1.38)$(0.96)$(3.66)$(2.82)Weighted average shares — basic and diluted94,215 80,091 93,707 77,173 Other comprehensive income (loss):Unrealized gain on investment securities$594 $2,228 $1,280 $1,061 Unrealized loss on foreign currency(21)— (49)— Total other comprehensive income573 2,228 1,231 1,061 Comprehensive loss$(129,518)$(74,600)$(341,271)$(216,752)

See the accompanying notes to these unaudited condensed consolidated financial statements.

4

Table of Contents

Crinetics Pharmaceuticals, Inc